Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Acelyrin Inc (SLRN)

Acelyrin Inc (SLRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 316,027
  • Shares Outstanding, K 100,326
  • Annual Sales, $ 0 K
  • Annual Income, $ -381,640 K
  • EBIT $ -336 M
  • EBITDA $ -346 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.60

Options Overview Details

View History
  • Implied Volatility 313.12% ( +59.35%)
  • Historical Volatility 84.78%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 313.12% on 12/20/24
  • IV Low 27.11% on 10/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 322
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 2,403
  • Open Int (30-Day) 1,847

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.88
  • Number of Estimates 5
  • High Estimate -0.72
  • Low Estimate -1.03
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -17.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.09 +3.08%
on 12/23/24
5.03 -36.72%
on 11/25/24
-1.52 (-32.34%)
since 11/22/24
3-Month
3.09 +3.08%
on 12/23/24
6.52 -51.23%
on 10/17/24
-1.76 (-35.63%)
since 09/23/24
52-Week
3.09 +3.08%
on 12/23/24
8.89 -64.21%
on 03/01/24
-3.94 (-55.34%)
since 12/22/23

Most Recent Stories

More News
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

SLRN : 3.18 (+0.95%)
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

SLRN : 3.18 (+0.95%)
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

SLRN : 3.18 (+0.95%)
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

SLRN : 3.18 (+0.95%)
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript

SLRN earnings call for the period ending September 30, 2023.

SLRN : 3.18 (+0.95%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acelyrin, Inc. - SLRN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...

SLRN : 3.18 (+0.95%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acelyrin, Inc. - SLRN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...

SLRN : 3.18 (+0.95%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acelyrin, Inc. - SLRN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...

SLRN : 3.18 (+0.95%)
Why Acelyrin Stock Plummeted 59% This Week

The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate.

SLRN : 3.18 (+0.95%)
Stocks Retreat as Tech Stocks Fall on Weakness in Oracle and Apple

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 5,974.07 (+0.73%)
SPY : 594.69 (+0.60%)
$DOWI : 42,906.95 (+0.16%)
DIA : 428.89 (+0.08%)
$IUXX : 21,503.17 (+1.01%)
QQQ : 522.87 (+0.81%)
ORCL : 169.14 (-0.31%)
NTRS : 102.59 (+0.11%)
ETN : 337.71 (-0.12%)
AAPL : 255.27 (+0.31%)
SLRN : 3.18 (+0.95%)
CMA : 61.86 (+1.14%)

Business Summary

Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.

See More

Key Turning Points

3rd Resistance Point 3.35
2nd Resistance Point 3.28
1st Resistance Point 3.23
Last Price 3.18
1st Support Level 3.11
2nd Support Level 3.04
3rd Support Level 2.99

See More

52-Week High 8.89
Fibonacci 61.8% 6.67
Fibonacci 50% 5.99
Fibonacci 38.2% 5.30
Last Price 3.18
52-Week Low 3.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar